# US Opioid Deaths Drop 38% but Fentanyl and New Adulterants Pose Emerging Threats

The opioid epidemic in the United States is showing signs of progress after years of devastation, with overdose deaths dropping significantly from over 110,000 in 2023 to around 75,000 in 2025, according to the American Medical Association. Provisional CDC data reveals an even steeper decline of nearly 38% between October 2023 and October 2025, from 109,703 to 68,408 deaths, marking 12 straight months of decreases as reported by CBS News. Listeners, this turnaround comes after a peak driven by illicitly manufactured fentanyl, which fueled the crisis, but local trends like those in Hennepin County, Minnesota, paint a mixed picture—fentanyl was involved in 86% of opioid deaths from January to June 2025, and both deaths and hospital visits rose after a 2024 downturn, per the county's April 9, 2026 update.

Despite national gains, challenges persist. The AMA warns the epidemic is evolving into a more complex threat, with nearly 60% of 2025 deaths involving multiple substances, including emerging adulterants like medetomidine—a veterinary sedative causing profound sedation and low blood pressure, as noted in the CDC's April 2 Health Alert. Globally, the World Health Organization reports opioids drive about 450,000 of 600,000 annual drug-related deaths, affecting 61 million people with non-medical use in 2023. In the U.S., a Weill Cornell Medicine survey from January 2026 shows 88% of adults across political lines view opioid overdoses as a very serious crisis, though conservatives emphasize personal responsibility while liberals point to pharmaceutical companies.

Funding remains volatile amid these shifts. Over $1.5 billion in State Opioid Response grants were awarded for prevention and treatment, alongside settlement funds, but SAMHSA grant disruptions and proposed 2026 budget cuts to CDC and SAMHSA threaten progress, STAT News reports. The Congressional Budget Office outlines federal strategies like boosting prescription monitoring, expanding telehealth and Medicaid for treatment, increasing naloxone access, and disrupting illicit supply chains. The AMA pushes for removing barriers to buprenorphine and methadone—prescriptions for buprenorphine jumped from 1.4 million in 2012 to 15.4 million in 2024—plus over-the-counter naloxone and parity enforcement in insurance.

Experts at the Rx and I

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI

This episode includes AI-generated content.